Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VHH72-Fc
- Development stage
- Unknown
- Lead developer
- ExeVir Bio
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Intranasal, Intraperitoneal
01
Overview
**VHH72-Fc** is a bivalent fusion protein consisting of the camelid-derived single-domain antibody (nanobody) VHH72 fused to a human IgG1 Fc domain, developed by researchers at VIB-Ghent University. It exhibits potent neutralizing activity against both SARS-CoV-1 and SARS-CoV-2 by binding to a highly conserved epitope in the receptor binding domain (RBD) of the viral spike protein, preventing interaction with the human ACE2 receptor and destabilizing the spike. This broad-spectrum action targets sarbecoviruses, with demonstrated prophylactic and therapeutic efficacy in K18-hACE2 mice and hamsters via intraperitoneal or intranasal administration; an affinity-enhanced version advanced to clinical testing by ExeVir Bio.[1][2][4][7]
- Other names
- rimteravimab
02
Targets
Omicron RBD (SARS-CoV-2 Omicron spike receptor-binding domain)RBD (SARS-CoV-2 spike receptor-binding domain)
Beyond the preview
Go deeper on VHH72-Fc.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VHH72-Fc.